Patient access schemes (PAS) – process revision

From November 2020 our process has changed to align the arrangements for Patient Access Schemes (PAS) across all submissions.

Companies can now submit a PAS or offer an improved PAS for all submissions following the New Drugs Committee meeting. Previously this only applied to submissions for medicines eligible for a Patient and Clinician Engagement (PACE) meeting (https://www.scottishmedicines.org.uk/how-we-decide/pace/). This change encompasses both simple and complex schemes.

More information can be found in the ‘Guidance to submitting companies for completion of the New Product Assessment Form (NPAF)’.